Wisconsin is currently home to 1264 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596
Recruiting
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Local Institution - Unk057, Madison, Wisconsin
Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Register for Updates
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642
Recruiting
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/14/2025
Locations: Research Site, Milwaukee, Wisconsin
Conditions: B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Register for Updates
National Cancer Institute "Cancer Moonshot Biobank"
NCT04314401
Recruiting
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
08/14/2025
Locations: Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin
Conditions: Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Acute Myeloid Leukemia, Metastatic Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Multiple Myeloma, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Fallopian Tube Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Melanoma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Triple-Negative Breast Carcinoma, Esophageal Carcinoma, Gastric Carcinoma
Register for Updates
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848
Recruiting
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclita... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Langlade Hospital and Cancer Center, Antigo, Wisconsin
Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Register for Updates
The ENCIRCLE Trial
NCT04153292
Recruiting
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
Register for Updates
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
NCT04133636
Recruiting
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Multiple Myeloma
Register for Updates
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Warm Autoimmune Hemolytic Anemia
Register for Updates
Pan Tumor Rollover Study
NCT03899155
Recruiting
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Local Institution - 0065, Madison, Wisconsin
Conditions: Cancer
Register for Updates
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/13/2025
Locations: Allegiance Research Specialists, Milwaukee, Wisconsin
Conditions: Obesity
Register for Updates
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343
Recruiting
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/13/2025
Locations: Froedtert & Medical College of Wisconsin - Clinical Cancer Center - Froedtert Hospital - Courage Cli, Milwaukee, Wisconsin
Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
Register for Updates
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
NCT06568172
Recruiting
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses hig... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Gundersen Lutheran Medical Center, La Crosse, Wisconsin
Conditions: Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma, Resectable Head and Neck Cutaneous Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Register for Updates
SIMPLAAFY Clinical Trial
NCT06521463
Recruiting
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Bellin Health, Green Bay, Wisconsin
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates